Search Results - Wimbury, David H.

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Nefecon® (Budesonide) Selectively Reduces Circulating Levels of BAFF (BLyS) and Soluble BCMA and TACI in IgA Nephropathy: FR-OR37

    Nefecon® (Budesonide) Selectively Reduces Circulating Levels of BAFF (BLyS) and Soluble BCMA and TACI in IgA Nephropathy: FR-OR37 by Molyneux, Karen, Barratt, Jonathan, Wimbury, David H.

    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Targeted Release Formulation Budesonide (Nefecon) Selectively Reduces Circulating Levels of Chemokines Critical to Immune Cell Trafficking to Peyer Patches in IgA Nephropathy: PO1453

    Targeted Release Formulation Budesonide (Nefecon) Selectively Reduces Circulating Levels of Chemokines Critical to Immune Cell Trafficking to Peyer Patches in IgA Nephropathy: PO14... by Molyneux, Karen, Wimbury, David H., Bhachu, Jasraj S., Muto, Masahiro, Stone, Andrew M., Barratt, Jonathan

    Get full text
    Article
    Save to List
    Saved in:

Search Tools: